Drugs that contain Ivacaftor
1. Drug name - KALYDECO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(4 years from now) | |
| US7495103 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
May, 2027
(4 years from now) | |
| CN102652128A | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Mar, 2015
(7 years ago) | |
| CN101935301A | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN107501099A | VERTEX PHARMS | Atp-Binding Cassette Transport Protein Modulators |
Jun, 2025
(2 years from now) | |
| CN101891680A | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN104788328B | VERTEX PHARMS | Atp-Binding Cassette Transport Protein Modulators |
Jun, 2025
(2 years from now) | |
| CN104788328A | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN103641765A | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN101935301B | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN103641765B | VERTEX PHARMS | Atp-Binding Cassette Transport Proteins Regulating Agent |
Jun, 2025
(2 years from now) | |
| CN107501099B | VERTEX PHARMS | Modulator Of Atp-Binding Cassette Transport Protein |
Jun, 2025
(2 years from now) | |
| CN101006076B | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN101006076A | VERTEX PHARMS | Regulator Of Atp-Abc Transport Protein |
Jun, 2025
(2 years from now) | |
| CN101891680B | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN101384172B | VERTEX PHARMS | N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form |
Dec, 2026
(4 years from now) | |
| CN101384172A | VERTEX PHARMS | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| IN282654B | VERTEX PHARMS | Modulators Of Atpbinding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP1773816A2 | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jul, 2020
(2 years ago) | |
| EP1773816B1 | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jul, 2020
(2 years ago) | |
| EP2489659B1 | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP3216787A1 | VERTEX PHARMS | Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2489659A1 | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2502911A2 | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2502911A3 | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2502911B1 | VERTEX PHARMS | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP3216787B1 | VERTEX PHARMS | Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP1993360A2 | VERTEX PHARMS | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP1993360A4 | VERTEX PHARMS | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP3219705A1 | VERTEX PHARMS | Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP3219705B1 | VERTEX PHARMS | Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP1993360B1 | VERTEX PHARMS | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jun, 2025
(2 years from now) | |
| US8354427 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jul, 2026
(3 years from now) | |
| US9670163 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(4 years from now) | |
| US8410274 | VERTEX PHARMS | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(4 years from now) | |
| US8324242 | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Aug, 2027
(4 years from now) | |
| US10646481 | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Aug, 2029
(6 years from now) | |
Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; Method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; method of treating cystic fibrosis; Method of treating cystic fibrosis; Method of treating cystic fibrosis; method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 150MG | TABLET;ORAL | Prescription |
2. Drug name - KALYDECO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8754224 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(4 years from now) | |
| US7495103 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
May, 2027
(4 years from now) | |
| CN102652128A | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Mar, 2015
(7 years ago) | |
| CN101935301A | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN107501099A | VERTEX PHARMS INC | Atp-Binding Cassette Transport Protein Modulators |
Jun, 2025
(2 years from now) | |
| CN101891680A | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN104788328B | VERTEX PHARMS INC | Atp-Binding Cassette Transport Protein Modulators |
Jun, 2025
(2 years from now) | |
| CN104788328A | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN103641765A | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN101935301B | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN103641765B | VERTEX PHARMS INC | Atp-Binding Cassette Transport Proteins Regulating Agent |
Jun, 2025
(2 years from now) | |
| CN107501099B | VERTEX PHARMS INC | Modulator Of Atp-Binding Cassette Transport Protein |
Jun, 2025
(2 years from now) | |
| CN101006076B | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN101006076A | VERTEX PHARMS INC | Regulator Of Atp-Abc Transport Protein |
Jun, 2025
(2 years from now) | |
| CN101891680B | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| CN101384172B | VERTEX PHARMS INC | N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form |
Dec, 2026
(4 years from now) | |
| CN101384172A | VERTEX PHARMS INC | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| IN282654B | VERTEX PHARMS INC | Modulators Of Atpbinding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP1773816A2 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jul, 2020
(2 years ago) | |
| EP1773816B1 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jul, 2020
(2 years ago) | |
| EP2489659B1 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP3216787A1 | VERTEX PHARMS INC | Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2489659A1 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2502911A2 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2502911A3 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP2502911B1 | VERTEX PHARMS INC | Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP3216787B1 | VERTEX PHARMS INC | Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters |
Jun, 2025
(2 years from now) | |
| EP1993360A2 | VERTEX PHARMS INC | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP1993360A4 | VERTEX PHARMS INC | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP3219705A1 | VERTEX PHARMS INC | Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP3219705B1 | VERTEX PHARMS INC | Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| EP1993360B1 | VERTEX PHARMS INC | Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide |
Dec, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629162 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jun, 2025
(2 years from now) | |
| US8354427 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jul, 2026
(3 years from now) | |
| US8410274 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(4 years from now) | |
| US9670163 | VERTEX PHARMS INC | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
Dec, 2026
(4 years from now) | |
| US8324242 | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Aug, 2027
(4 years from now) | |
| US10646481 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(6 years from now) | |
| US8883206 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(10 years from now) | |
| US10272046 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Feb, 2033
(10 years from now) | |
Treatment: Treatment of a moderate mild clinical phenotype of cf using ivacaftor in a patient age 6 months to <6 years who has one cftr mutation repsonsive to ivacaftor based on clinical and/or in vitro assay data; use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; treatment of a moderate to mild clinical phenotype of cf using ivacaftor in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data; Method of treating cystic fibrosis; treatment of cystic fibrosis using ivacaftor in a patient age 6 months to <6 years who has a r117h mutation in the cftr gene; method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has a r117h mutation in the cftr gene; Method of treating cystic fibrosis; treatment of cf in a patient age 6 months to < 6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data using a solid composition comprising amorphous (less than about 30% crystalline) ivacaftor; treatment of cf in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data using a solid composition comprising amorphous (less than about 30% crystalline) ivacaftor; Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; method of treating cystic fibrosis; treatment of cystic fibrosis using ivacaftor in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; Treatment of cf in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046; treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046
Dosage: GRANULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 25MG/PACKET | GRANULE;ORAL | Prescription |
| 50MG/PACKET | GRANULE;ORAL | Prescription |
| 75MG/PACKET | GRANULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.